Originally posted at bloomberg.com
October 8, 2012, By Shannon Pettypiece

Eli Lilly & Co. (LLY)’s experimental Alzheimer’s treatment slowed memory loss and cognitive decline in early-stage patients by about 30 percent, offering the first evidence that a medication may hamper the course of the ailment, researchers said.

The benefit, though small, supports further research targeting a protein called beta amyloid, said Rachelle Doody, chairwoman of Alzheimer’s disease research at Baylor College of Medicine who presented the findings today at the American Neurological Association meeting in Boston.

Read the full story at bloomberg.com.